Share This Page

Support & Insight for the Autumn of Life

ARIA in Lacanemab, Donanemab and Aduhelm

A neuroradiologist at the Mayo Clinic in Jacksonville, FL warns that increased use of monoclonal antibody treatment for Alzheimer's has also led to the discovery of amyloid-related imaging abnormalities -- ARIA. Find out more.
ARIA

An article published in RadioGraphics examines the use of monoclonal antibody therapies for treating Alzheimer disease (AD) and alerts physicians to be on the lookout for a potential side effect, amyloid-related imaging abnormalities (ARIA), which cause brain swelling and/or hemorrhage.

AD is the most common form of dementia worldwide. While previous treatment methods focused on addressing AD symptoms, recent approvals of monoclonal antibodies have provided a path to target the underlying disease itself.

DRUG % ARIA
Lecanemab17.3%
Donanemab31.4%
Adulehm35 %

The main pathologic feature of AD is a buildup of toxic amyloid-B. Disease-modifying drugs like monoclonal antibodies clear toxic amyloid-B protein from the brain.

In June 2021, the U.S. Food and Drug Administration (FDA) gave accelerated approval for aducanumab (Aduhelm) as a treatment for AD. The FDA has determined that there is substantial evidence that aducanumab reduces amyloid-B plaques in the brain and that the reduction in these plaques is likely to result in benefits to patients.

“FDA-approved drugs such as aducanumab, as well as upcoming newer-generation drugs, have provided an exciting new therapy focused on reducing the amyloid plaque burden in Alzheimer disease,” said Amit K. Agarwal, MBBS, MD, lead author of the article and neuroradiologist at Mayo Clinic in Jacksonville, FL.

Although this groundbreaking new therapy has shown benefits in patients with AD, it is not without complications. Increased use of monoclonal antibodies led to the discovery of amyloid-related imaging abnormalities (ARIA).

The abnormalities have been further classified into two categories, ARIA-E, representing edema and/or effusion, and ARIA-H, representing hemorrhage. ARIA is thought to be caused by increased vascular permeability following an inflammatory response, leading to the leakage of blood products and fluid into surrounding tissues.

Agarwal RG fig 10 Alzheimer's Disease treatment side effectsSevere ARIA-E (effusion) in a 76-year old man with worsening headaches receiving aducanumab therapy for AD. Axial brain MR images from December 2021 (3 weeks after full dose) show multifocal exudates along the sulci with FLAIR hyperintensity (arrows in A), measuring more than 10 cm (severe) with subtle leptomeningeal enhancement (B). Treatment was suspended, and complete resolution of effusion was noted after cessation of therapy.

Close Collaboration with Neurologists Needed

Patients with ARIA sometimes have headaches, but they are usually asymptomatic and only diagnosable with MRI.

“It is essential for the radiologist to recognize and monitor ARIA,” Dr. Agarwal said. “As the use of monoclonal antibodies becomes more widespread, close collaboration between neurologists and radiologists is needed before and during therapy to plan for image monitoring per established guidelines.”

ARIA-E is the most common side effect of monoclonal antibody treatment.

In two phase III trials, 35% of patients on the approved dose had ARIA-E. These trials also showed that most ARIA-E cases were clinically asymptomatic and that 98% were resolved at follow-up imaging. ARIA-E occurred most frequently between three and six months of treatment, with incidence sharply dropping after the first nine months.

ARIA-H typically occurs in about 15 to 20% of patients treated with monoclonal antibodies. Unlike ARIA-E, ARIA-H is not transient and does not resolve over time.

Most patients with asymptomatic ARIA meeting specific radiographic and clinical criteria may continue to receive treatment.

The vast majority of patients with ARIA-E can continue therapy either with or without temporary suspension. However, in ARIA-H patients, therapy decisions depend on the severity of ARIA-H and whether it is stabilized. The detection of 10 or more new microhemorrhages requires permanent discontinuation of therapy.

“Immunotherapy is becoming more prevalent in managing dementia, and the recently approved monoclonal antibody therapy offers an exciting new frontier,” Dr. Agarwal said.

“Identifying and monitoring ARIA plays a vital role in safety monitoring and management decisions in anti-amyloid monoclonal antibody trials and clinical practice.”

According to Dr. Agarwal, when ARIA is present, a conservative monitoring plan should be established with a multidisciplinary approach that includes neurologists and radiologists familiar with the clinical and imaging aspects of the condition.

MORE INFO:

Amyloid-related Imaging Abnormalities in Alzheimer Disease Treated with Anti-Amyloid-β Therapy

Radiologist’s Role in Anti-Amyloid Therapy for Alzheimer Disease

Email me when people comment
Notify of
guest

This site uses Akismet to reduce spam. Learn how your comment data is processed.

0 Comments
Inline Feedbacks
View all comments
Edited by:
Picture of Hanna Levi Julian

Hanna Levi Julian

This site was inspired by my Mom’s autoimmune dementia.

It is a place where we separate out the wheat from the chafe, the important articles & videos from each week’s river of news. Google gets a new post on Alzheimer’s or dementia every 7 minutes. That can overwhelm anyone looking for help. This site filters out, focuses on and offers only the best information. it has helped hundreds of thousands of people since it debuted in 2007. Thanks to our many subscribers for your supportive feedback.

The site is dedicated to all those preserving the dignity of the community of people living with dementia.

Peter Berger, Editor

Share this page To

Related:

x-ray, mri, ct scan
Advocacy

11 Myths About Alzheimer’s

With all the information out there about Alzheimer’s, it’s hard to tease out which things are true, and which things are not. Some “facts” are really just myths. Find out which is which.

Read More »
Understanding Dementia

Memory & Amyloid

Amyloid is one of the leading culprits behind Alzheimer’s. Scientists know it damages memory by killing brain cells. Now research reveals how amyloid triggers memory loss in perfectly healthy brain cells as well. Learn more about how Alzheimer’s develops.

Read More »
Share to Facebook
Twitter
LinkedIn

This site was inspired by my Mom’s autoimmune dementia.

It is a place where we separate out the wheat from the chafe, the important articles & videos from each week’s river of news. Google gets a new post on Alzheimer’s or dementia every 7 minutes. That can overwhelm anyone looking for help. This site filters out, focuses on and offers only the best information. it has helped hundreds of thousands of people since it debuted in 2007. Thanks to our many subscribers for your supportive feedback.

The site is dedicated to all those preserving the dignity of the community of people living with dementia.

Peter Berger, Editor

Visit Alzheimer's Weekly On

0
Would love your thoughts, please comment.x
()
x
News, Treatments, Care Tips, Diet

Alzheimer's & Dementia Weekly Newsletter: Free

Free. Care & Treatment. Research & Prevention

This site was inspired by my Mom’s autoimmune dementia.

It is a place where we separate out the wheat from the chafe, the important articles & videos from each week’s river of news. Google gets a new post on Alzheimer’s or dementia every 7 minutes. That can overwhelm anyone looking for help. This site filters out, focuses on and offers only the best information. It has helped hundreds of thousands of people since it debuted in 2007. Thanks to our many subscribers for your supportive feedback.

The site is dedicated to all those preserving the dignity of the community of people living with dementia.

Peter Berger, Editor

News to Get at the Truth

Subscribe To Our Weekly Newsletter